A Wistar Institute study found in preclinical models that ovarian cancer cells surviving chemotherapy can release fructose that weakens neighboring tumor-cell attachments and promotes metastasis, while high dietary fructose and cholesterol-lowering drugs produced related effects that researchers say warrant further study.
By yourNEWS Media Newsroom
Fructose may play an unexpected role in helping ovarian cancer spread by acting as a chemical signal between tumor cells, according to new preclinical research from The Wistar Institute that could raise questions about diet, cholesterol metabolism and the medications commonly used to lower cholesterol.
The study, published Aug. 4, 2026, in the peer-reviewed journal Nature Aging, examined what happens after some ovarian cancer cells survive chemotherapy. Researchers found that those surviving cells released molecules capable of changing the behavior of neighboring tumor cells — and identified fructose as one of the substances driving that response.
Rather than simply providing fuel for the cancer cells, fructose appeared to alter their internal cholesterol production. As cholesterol declined, connections between neighboring cancer cells weakened, making it easier for individual cells to detach and move elsewhere.
That process is significant because ovarian cancer recurrence frequently involves cancer spreading throughout the abdominal cavity.
Nearly all ovarian cancer patients receive platinum-based chemotherapy, according to the researchers. Although tumors often initially respond well to treatment, the disease returns in most patients. Metastasis ultimately accounts for roughly 90% of ovarian cancer deaths, the study stated.
The research team was led by Aidan Cole, Ph.D., a postdoctoral fellow in the laboratory of Katherine Aird, Ph.D., professor and co-leader of the Molecular and Cellular Oncogenesis Program in the Ellen and Ronald Caplan Cancer Center at The Wistar Institute.
Instead of focusing only on the cancer cells that survive treatment, Cole and his colleagues investigated the substances those surviving cells release into their surrounding environment.
Researchers collected molecules produced by chemotherapy-surviving ovarian cancer cells and then exposed other tumor cells to those substances.
The molecules alone significantly increased the ability of the untreated cancer cells to spread, according to the study.
“As far as we know, this is the first time anyone has shown, in a preclinical model rather than just a dish, that it’s the molecules these cells release — not the cells themselves — that drive the cancer’s spread,” Cole said.
The team then worked to identify how those released molecules were altering the neighboring cells.
Using a CRISPR screen and other large-scale analytical techniques, researchers found that fructose produced by the chemotherapy-surviving cells was functioning as a signal.
Once neighboring cancer cells encountered the fructose, their cholesterol production declined.
Cholesterol is commonly discussed in the context of cardiovascular disease, but it also performs structural functions within cells. In the Wistar study, the researchers described cholesterol as helping cancer cells maintain their connections to one another, functioning in effect as a type of biological glue.
When intracellular cholesterol levels dropped, those connections became weaker. Tumor cells were then better able to separate from one another and migrate, creating conditions favorable to metastasis.
Earlier research examining glucose transporters has also found differences in transporter isoform expression between normal ovarian tissue and cancerous ovarian tissue.
The Wistar researchers found that the fructose effect was not limited to molecules produced after chemotherapy.
When preclinical models were exposed to high levels of dietary fructose comparable to amounts found in sugary beverages, cancer spread increased even in the absence of chemotherapy.
That finding prompted the researchers to consider whether dietary fructose itself could influence tumor behavior.
High-fructose corn syrup can account for an estimated 8% to 20% of total daily calories in some people, according to the study. Earlier research has also examined cancer cells’ ability to use fructose to support proliferation, while broader research has explored the relationship between high sugar consumption and cancer metabolism.
The metabolic consequences of excessive sugar intake have also been discussed extensively in Robert Lustig’s book “Fat Chance.”
The new study does not establish that consuming fructose causes ovarian cancer to spread in humans. The experiments were performed in preclinical models, and researchers emphasized that the findings have not yet been demonstrated in patients.
The cholesterol connection raised another question because millions of Americans take medications designed specifically to reduce cholesterol production.
About 39 million people in the United States use statins, according to the researchers.
In the study, statins by themselves reduced the strength of the connections between cancer cells, making it easier for the cells to detach.
Because chemotherapy-surviving cells appeared to promote metastasis partly by suppressing cholesterol production, the researchers are now investigating whether statins could interact with that same biological pathway and potentially affect chemotherapy outcomes.
Aird cautioned that the results remain preliminary and should not be interpreted as instructions for patients to discontinue prescribed cholesterol medications.
“We haven’t tested this effect in patients yet, but it raises questions about combining cholesterol-lowering drugs with chemotherapy, especially since ovarian cancer is most common in postmenopausal women who are often already on statins,” Aird said.
The study therefore identifies a potential treatment question rather than establishing that statins worsen ovarian cancer outcomes in people.
Clinical researchers have previously examined other supportive interventions for patients receiving platinum-based chemotherapy. One study involving ovarian cancer patients treated with cisplatin reported improvements in kidney filtration and quality-of-life measures among patients receiving glutathione treatment.
The Wistar findings could also have implications beyond ovarian cancer.
Ovarian tumors commonly spread within the abdominal cavity rather than immediately metastasizing to distant organs, and researchers believe the fructose-cholesterol pathway may be relevant to other cancers that spread through nearby areas of the torso.
“We think other cancers that spread within the torso — pancreatic, colon, liver — could behave similarly. We can’t call it universal yet, but we think the effects are not just limited to ovarian cancer,” Aird said.
Aird and Cole are now planning additional studies to determine whether the same mechanism can be reproduced in several other cancer types.
The research also adds another dimension to understanding what happens after chemotherapy kills most, but not all, tumor cells.
Cancer recurrence has traditionally focused heavily on the properties of surviving malignant cells themselves. The Wistar study suggests their importance may also lie in what they release into the surrounding tumor environment.
In this case, those surviving cells appeared capable of influencing neighboring cells through fructose, altering cholesterol production and weakening the physical connections that help keep tumor cells together.
That mechanism could help explain how populations of cancer cells that survive initial treatment contribute to later metastatic disease.
At the same time, the findings involving dietary fructose and statins create questions that researchers say require clinical investigation before conclusions can be drawn for patients.
The study does not establish that ovarian cancer patients should eliminate fructose from their diets, nor does it demonstrate that statins should be discontinued. Researchers specifically cautioned against stopping prescribed medications on the basis of the findings.
Instead, the results identify metabolic pathways that may eventually help researchers better understand recurrence, chemotherapy response and the conditions that enable tumor cells to spread.
The research was supported by grants from the National Institutes of Health, the American Cancer Society, the Ovarian Cancer Research Alliance, the Congressionally Directed Medical Research Program and other organizations.
Explainer Infographic
Comments